Best Cardiologists for Coronary Intervention in Texas

Ochsner LSU Health Shreveport | San Antonio, TX | Interventional cardiology, cardiogenic shock

Steven Bailey holds the Malcolm Feist Chair of Interventional Cardiology at LSU Health Shreveport and chairs the Department of Medicine. His practice in San Antonio focuses on high-risk coronary intervention, including patients presenting in cardiogenic shock — a life-threatening state where the heart can no longer pump enough blood to sustain the body.

Dr. Bailey was the first author on the 2019 SCAI consensus statement that established a standardized classification system for cardiogenic shock — a paper cited nearly 1,000 times ¹. Before that framework existed, there was no common language across hospitals for describing how sick a patient in shock actually was. The classification is now used in clinical trials, transfer protocols, and ICU care decisions across the country. He also contributed to the 2011 ACC/AHA/SCAI guidelines for percutaneous coronary intervention, one of the most referenced documents in interventional cardiology ²³, and to the 2009 focused updates on STEMI management that shaped how hospitals respond to heart attacks ⁴⁵. His research [241 published works, h-index 48] spans over two decades of guideline-level work in interventional procedures.

Houston Methodist Clear Lake Hospital / Memorial Hermann-Texas Medical Center | Houston, TX | Interventional cardiology, endovascular medicine

Salman Arain is Associate Professor of Cardiovascular Medicine at McGovern Medical School at UTHealth Houston. He practices at Houston Methodist Clear Lake and Memorial Hermann, seeing patients with coronary artery disease, peripheral vascular disease, and structural heart conditions including those being evaluated for transcatheter aortic valve replacement.

One of Dr. Arain's research contributions focuses on how time affects outcomes in STEMI — the most serious type of heart attack. A 2015 study he contributed to in Catheterization and Cardiovascular Interventions found that total ischemic time (the full time from symptom onset to artery reopening) was a stronger predictor of mortality and infarct size than door-to-balloon time alone ⁷. That finding matters for patients because it argues for calling 911 at the first symptom rather than waiting to see if chest pain resolves. He also co-authored a 2019 analysis in The American Journal of Medicine on heart attack outcomes in patients with influenza and other respiratory infections ⁶, and contributed to a single-center TAVR risk-prediction study comparing transcatheter and surgical valve replacement in high-risk patients ⁸. His broader research [99 published works] spans endovascular and coronary interventional care.

Texas Health Presbyterian Hospital Dallas / Medical City Dallas | Dallas, TX | Interventional cardiology, peripheral vascular intervention

Tony Das practices at Texas Health Presbyterian Hospital Dallas and Medical City Dallas, with affiliations at Hunt Regional Medical Center. His published work covers coronary and peripheral interventional procedures, including techniques for treating calcified lesions and in-stent restenosis.

A 2013 study Dr. Das led in Catheterization and Cardiovascular Interventions examined orbital atherectomy technique optimization in calcified peripheral lesions — a real-world registry analysis showing that a specific change in device usage led to fewer adverse events regardless of calcium burden or patient comorbidities ¹². That kind of technique-level research is relevant for patients with heavily calcified coronary or peripheral arteries, where standard balloon angioplasty often fails. He also contributed to the ARMOUR trial, a multicenter study of a proximal cerebral protection device during carotid artery stenting that reported zero strokes in symptomatic patients ¹¹, and led work on excimer laser therapy for femoropopliteal in-stent restenosis ¹³. His published research [47 works, h-index 18] covers a range of catheter-based revascularization techniques.

Baylor Scott & White Heart and Vascular Hospital – Dallas | Dallas, TX | Interventional cardiology, coronary chronic total occlusions

Subhash Banerjee is Chief of Cardiovascular Research and Innovation at Baylor Scott & White Heart and Vascular Hospital in Dallas, where he also holds the Paul J. Thomas Endowed Chair in Cardiology and serves as Clinical Professor of Medicine at Texas A&M. He has published extensively on coronary artery disease management, with a particular focus on chronic total occlusions (CTOs) — complete blockages in coronary arteries that are among the most technically difficult cases in interventional cardiology.

A 2013 study Dr. Banerjee contributed to in Catheterization and Cardiovascular Interventions found that coronary CTOs were highly prevalent in a veteran population and associated with more extensive comorbidities and a greater likelihood of referral for bypass surgery — with PCI attempted at similar rates in CTO and non-CTO patients ¹⁶. That work helped establish how often these blockages are present and how they are managed in practice. He also contributed to a 2009 JACC study on drug-eluting stents in saphenous vein graft lesions ¹⁹, to widely cited research on perioperative management of patients with coronary stents ²⁰, and to a 2017 meta-analysis of PCSK9 inhibitors across 35 randomized trials ¹⁸. With 686 published works and an h-index of 57, his research output is among the largest in this group.

Houston Methodist Hospital / Baylor St. Luke's Medical Center | Houston, TX | Interventional cardiology, cardiovascular medicine

Salman Bandeali practices at Houston Methodist Hospital and Baylor St. Luke's Medical Center in Houston. His research [49 published works] covers coronary artery bypass surgery outcomes, cardiovascular risk in rheumatologic disease, and lipid metabolism.

Dr. Bandeali contributed to a 2013 meta-analysis in The American Journal of Cardiology that compared mortality after isolated coronary artery bypass grafting in women versus men across multiple studies ²¹. Sex differences in CABG outcomes are clinically meaningful — women have historically had higher operative mortality than men, and understanding that gap matters for informed consent and surgical planning. He also led a 2012 study examining preoperative ACE inhibitor therapy and outcomes in isolated CABG patients ²⁵, and has published on HDL's role in atherosclerosis ²³ and diastolic dysfunction in patients with rheumatoid arthritis ²² — relevant because autoimmune conditions significantly raise cardiovascular risk.

Matagorda Regional Medical Center / HCA Houston Healthcare Clear Lake | Bay City, TX | Interventional cardiology, peripheral vascular intervention

George Hanna practices in Bay City at Matagorda Regional Medical Center and holds affiliations with HCA Houston Healthcare Clear Lake and El Campo Memorial Hospital. His research covers catheter-based coronary and peripheral interventions, including early work on managing no-reflow — a complication where blood flow does not fully restore after an artery is opened.

A 2000 study Dr. Hanna contributed to in Catheterization and Cardiovascular Interventions examined intracoronary adenosine given during PCI for acute heart attack. In patients who received adenosine, the rate of no-reflow was 5.9% versus 28.6% in those who did not — a difference associated with lower in-hospital death rates ²⁶. He led similar work the year before on adenosine during rotational atherectomy, where patients who received it had no-reflow with MI in only 1.4% of cases compared to 11.6% in the control group ²⁸. Both studies were published before adenosine use in this context became routine, placing his work among the earlier clinical evidence for a now-common technique. He also published an early series on infrapopliteal catheter interventions for limb salvage in diabetic patients ²⁷.